{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:43:29Z","timestamp":1785527009595,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To assess the clinical performance of [\n                      <jats:sup>18<\/jats:sup>\n                      F]piflufolastat PET\/CT acquired on a total-body 194-cm LAFOV PET\/CT system in patients with prostate cancer, with particular focus on detection rate, site-specific disease distribution, and the association between PET findings and serum PSA levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective single-centre study included 103 consecutive patients with prostate cancer who underwent clinically indicated [\n                      <jats:sup>18<\/jats:sup>\n                      F]piflufolastat PET\/CT on 194-cm LAFOV PET\/CT. Indications were primary staging (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200942) or suspected recurrence (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200961). Only the 8-min acquisition dataset was analyzed. PET findings were assessed on a patient basis and across predefined anatomical sites. In the recurrence subgroup, the association between PSA and PET positivity was evaluated using Mann\u2013Whitney U test, logistic regression with log-transformed PSA, ROC analysis, and Spearman correlation with the number of positive sites.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, PET was positive in 91\/103 patients (88.3%), negative in 8\/103 (7.8%), and indeterminate in 4\/103 (3.9%). Positivity was observed in all patients scanned for primary staging (42\/42, 100.0%) and in 49\/61 patients (80.3%) referred for recurrence. The most frequent positive sites were primary lesion (57.3%), lymph nodes (35.0%), and bone (24.3%). In recurrence, PSA was significantly higher in PET-positive than in non-positive cases (median 2.40 vs. 0.42 ng\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Log-transformed PSA was significantly associated with PET positivity (OR 7.40, 95% CI 2.18\u201325.11;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), with an AUC of 0.912 (95% CI 0.828\u20130.974). PSA also correlated with the number of positive sites (rho\u2009=\u20090.620,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]piflufolastat PET\/CT on 194-cm LAFOV PET\/CT showed high clinical performance in prostate cancer, with strong PSA-dependent yield in recurrence and effective depiction of site-specific disease distribution.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07955-7","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:11:49Z","timestamp":1780125109000},"page":"5811-5820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical performance of [18F]piflufolastat PET\/CT on a 194-cm LAFOV PET\/CT system in prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Pierpaolo","family":"Alongi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-8858","authenticated-orcid":false,"given":"Agostino","family":"Chiaravalloti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Morea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"7955_CR1","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2967\/jnumed.120.250597","volume":"62","author":"BA Spencer","year":"2021","unstructured":"Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance evaluation of the uEXPLORER Total-Body PET\/CT scanner based on NEMA NU 2-2018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med. 2021;62:861\u201370. https:\/\/doi.org\/10.2967\/jnumed.120.250597.","journal-title":"J Nucl Med"},{"key":"7955_CR3","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1007\/s00259-021-05659-8","volume":"49","author":"J Wen","year":"2022","unstructured":"Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R. Determination of optimal (68) Ga-PSMA PET\/CT imaging time in prostate cancers by total-body dynamic PET\/CT. Eur J Nucl Med Mol Imaging. 2022;49:2086\u201395. https:\/\/doi.org\/10.1007\/s00259-021-05659-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR4","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1007\/s00259-023-06355-5","volume":"50","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen Z, Zhu Y, Zhao H, Li L, Huang G, et al. Total-body [(68) Ga]Ga-PSMA-11 PET\/CT improves detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:4096\u2013106. https:\/\/doi.org\/10.1007\/s00259-023-06355-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mp.16876","volume":"51","author":"H Yuan","year":"2024","unstructured":"Yuan H, Zhang G, Sun T, Ren J, Zhang Q, Xiang Z, et al. Kinetic modeling and parametric imaging of 18F-PSMA-11: an evaluation based on total-body dynamic positron emission tomography scans. Med Phys. 2024;51:156\u201366. https:\/\/doi.org\/10.1002\/mp.16876.","journal-title":"Med Phys"},{"key":"7955_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12149-024-02000-9","volume":"39","author":"X Sun","year":"2025","unstructured":"Sun X, Zhang G, Zhang Q, Yuan H, Jiang L, Sun T. Comparison of early and standard (18)F-PSMA-11 PET\/CT imaging in treatment-na\u00efve patients with prostate cancer. Ann Nucl Med. 2025;39:295\u2013302. https:\/\/doi.org\/10.1007\/s12149-024-02000-9.","journal-title":"Ann Nucl Med"},{"key":"7955_CR7","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00259-024-06620-1","volume":"51","author":"C Sachpekidis","year":"2024","unstructured":"Sachpekidis C, Pan L, Groezinger M, Strauss DS, Dimitrakopoulou-Strauss A. Combined whole-body dynamic and static PET\/CT with low-dose [(18)F]PSMA-1007 in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2024;51:2137\u201350. https:\/\/doi.org\/10.1007\/s00259-024-06620-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR8","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R, et al. The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51:3753\u201364. https:\/\/doi.org\/10.1007\/s00259-024-06797-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","volume":"5","author":"L Evangelista","year":"2022","unstructured":"Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, et al. [(68)Ga]Ga-PSMA Versus [(18)F]PSMA positron emission tomography\/computed tomography in the staging of primary and recurrent prostate cancer. a systematic review of the literature. Eur Urol Oncol. 2022;5:273\u201382. https:\/\/doi.org\/10.1016\/j.euo.2022.03.004.","journal-title":"Eur Urol Oncol"},{"key":"7955_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00259-022-05961-z","volume":"50","author":"I Alberts","year":"2023","unstructured":"Alberts I, Schepers R, Zeimpekis K, Sari H, Rominger A, Afshar-Oromieh A. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET\/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50:951\u20136. https:\/\/doi.org\/10.1007\/s00259-022-05961-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR12","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.Ccr-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4573.","journal-title":"Clin Cancer Res"},{"key":"7955_CR13","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00259-023-06301-5","volume":"50","author":"DE Oprea-Lager","year":"2023","unstructured":"Oprea-Lager DE, Gontier E, Garc\u00eda-Ca\u00f1amaque L, Gauth\u00e9 M, Olivier P, Mitjavila M, et al. [(18)F]DCFPyL PET\/CT versus [(18)F]fluoromethylcholine PET\/CT in biochemical recurrence of prostate cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging. 2023;50:3439\u201351. https:\/\/doi.org\/10.1007\/s00259-023-06301-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1148\/radiol.211824","volume":"303","author":"U Metser","year":"2022","unstructured":"Metser U, Zukotynski K, Mak V, Langer D, MacCrostie P, Finelli A, et al. Effect of (18)F-DCFPyL PET\/CT on the Management of patients with recurrent prostate cancer: results of a prospective multicenter registry trial. Radiology. 2022;303:414\u201322. https:\/\/doi.org\/10.1148\/radiol.211824.","journal-title":"Radiology"},{"key":"7955_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","volume":"48","author":"M Wondergem","year":"2021","unstructured":"Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, et al. (18)F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. Eur J Nucl Med Mol Imaging. 2021;48:521\u201331. https:\/\/doi.org\/10.1007\/s00259-020-04782-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7955_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/mnm.0000000000001652","volume":"44","author":"PG Maliha","year":"2023","unstructured":"Maliha PG, Nolet B, Ebrahim A, Abikhzer G, Chauss\u00e9 G, Bahoric B, et al. Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18 F PET\/CT in prostate cancer patients in early biochemical failure. Nucl Med Commun. 2023;44:187\u201393. https:\/\/doi.org\/10.1097\/mnm.0000000000001652.","journal-title":"Nucl Med Commun"},{"key":"7955_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/ju.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206:52\u201361. https:\/\/doi.org\/10.1097\/ju.0000000000001698.","journal-title":"J Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07955-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:07:47Z","timestamp":1785521267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7955"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07955-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective design of the study and the use of anonymized clinical and imaging data, the requirement for written informed consent was waived by the local Ethics Committee.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}